USFDA has finally given the green light to Allergan for its product Botox injection (onabotulinumtoxinA) for the new indication that is prevention of headaches associated with chronic migraine in adult patients. As per the survey this new indication is going to add $ 1 billion to the existing annual sales of $1.3 billion.
Other than this new indication of migraine which is already approved by FDA, Allergan is also evaluating its one more therapeutic activity against overactive bladder.
(Source: http://www.fiercepharma.com)
No comments:
Post a Comment